The next generation biopharmaceuticals

Interim Report – January to March 2017

2017-05-19

Interim Report – January to March 2017

Affibody Medical AB (publ) (“Affibody” or “the Company”), a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™, today issued its Interim Report for the first quarter 2017.

Financial Highlights

  • Revenue for the 1st Quarter 2017 was SEK 31.1 (20.9) m
  • Operating result for the quarter amounted to SEK 2.3 (-11.4) m
  • EBITDA for the quarter amounted to SEK 2.6 (-11.3) m
  • Net result for the quarter amounted to SEK 2.3 (-11.7) m
  • Cash flow for the quarter was SEK 18.0 (20.2) m
  • Cash and cash equivalents at the end of the period amounted to SEK 145.1 (27.3) m.

Significant Events during the Reporting Period

  • During the quarter, the first patient was dosed and evaluated in the clinical trial with ABY-029, to guide cancer surgery.

Significant Events after the Close of the Reporting Period

  • In May it was announced that we have decided to initiate a Phase II development with ABY-035, our proprietary psoriasis program.

Affibody is a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™.

Affibody is developing a portfolio of innovative drug projects and, in addition, offers the half-life extension technology, Albumod™, for outlicensing.

The company is currently developing four proprietary programs. The first three are therapeutic programs that targets prevention of liver disease, autoimmune diseases, and psoriasis respectively. The fourth program is a diagnostic imaging program that is directed primarily towards metastatic breast cancer.

Affibody also has ongoing commercial relationships with several companies such as AbClon, Biotest, Daewoong, Daiichi Sankyo, GE Healthcare, MedImmune, Nordic Nanovector, and Swedish Orphan Biovitrum.

Further information can be found at: www.affibody.com

Affibody in short

Affibody is a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™.

Upcoming reports Financial calendar

  • Year-end report (February 24, 2017)